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INTRODUCTION
Psoriasis is a chronic inflammatory disease caused 
by genetics and affected by other factors. It is charac-
terized by hyperproliferation and altered differentia-
tion of keratinocytes, T lymphocyte infiltration, and 
vascular changes (1,2). T lymphocytes, cytokines, and 
chemokines are the main components required for 
the initiation and development of the disease (2).
In addition to storing energy, adipose tissue is 
known to be an active endocrine organ regulating 
body metabolism by secretion of metabolically im-
AbSTRACT Psoriasis is a chronic, autoimmune, and inflammatory disease of 
unknown etiology, characterized by T lymphocyte mediated keratinocyte pro-
liferation. In recent years the relationship between psoriasis and adipose tissue 
cytokines has been reported. Psoriasis as a triggering factor for the immune and 
metabolic disorders can be associated with diabetes mellitus, abnormal lipid me-
tabolism, and metabolic syndrome. In this study we assessed the adipose tissue 
cytokines visfatin, adiponectin, and tumor necrosis factor-α (TNF-α) levels in pso-
riasis patients and evaluated the relationship between disease severity and cyto-
kines. The study included 42 patients with psoriasis and 42 healthy individuals. 
Visfatin, adiponectin, and TNF-α levels were measured in both the psoriasis and 
the control group. The disease severity index was assessed in psoriatic patients by 
means of PASI. The relationship between visfatin, adiponectin, TNF-α, PASI score, 
and obesity was evaluated.
When serum TNF-α, adiponectin, and visfatin levels of the patient group were com-
pared with those of the control group, the TNF-α levels were statistically higher (p 
= 0.00) and the adiponectin levels were statistically lower (p = 0.024). The visfatin 
levels were higher in the psoriatic patients compared to the control group, but 
this difference was not statistically significant (p = 0.73). The relationship between 
PASI-TNF-α and between PASI-adiponectin was statistically significant (p = 0.009 
and p = 0.004). A positive correlation was observed between body mass index 
(BMI) and visfatin (p = 0.031).
These results indicate that TNF-α and adiponectin play a part in psoriasis etio-
pathogenesis and can be used as parameters to evaluate the severity of the dis-
ease. However, the role of visfatin in psoriasis pathogenesis is unclear. Further clini-
cal studies are needed to clarify the effect of visfatin in psoriatic patients.
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portant proteins called adipokines, such as leptin, ad-
iponectin, visfatin, and cytokines. It also secretes che-
mokines, such as tumor necrosis factor alpha (TNF-α), 
interleukin (IL)-6, and the monocyte chemoattractant 
protein-1 (3). TNF-α is a 25 kDa transmembrane pro-
tein. It is a multifunctional proinflammatory and im-
munoregulatory cytokine, produced in macrophages, 
lymphocytes, and to a lesser extent in adipocytes. 
Functions of TNF-α include inflammation, apoptosis, 
production of IL-1, IL-6 cytokines, and the induction 
of insulin resistance (3-5). Adiponectin exhibits struc-
tural homology with collagen VIII, X, and the comple-
ment factor C1q (6). Adiponectin is associated with 
increased insulin sensitivity, the regulation of NFκB, 
and the inhibition of TNF-α. Adiponectin levels are in-
versely related to obesity, insulin resistance, and car-
diovascular disease. Hormone levels are known to be 
decreased in patients with type 2 diabetes mellitus, 
atherosclerosis, and obesity (4,7). Adiponectin reduc-
es T-cell activation and proliferation, inhibits phago-
cytosis, and increases the anti-inflammatory media-
tor IL-10. It also restrains TNF-α secretion by inhibiting 
the NFκB pathway. Adiponectin decreases the TNF-α 
induced inflammatory response by directly suppress-
ing TNF-α production. However, adiponectin secre-
tion from adipocytes is inhibited by TNF-α and IL-6. 
In the general population, adiponectin and the CRP 
plasma levels are inversely related (3,6,8). Visfatin is a 
newly discovered 52 kDa protein that plays a role in 
glucose homeostasis. It is preferentially expressed by 
visceral adipose tissue compared with subcutaneous 
fat, so it is called visfatin (7,8). Plasma visfatin levels 
are associated with obesity, visceral fat mass, type 2 
diabetes mellitus, and metabolic syndrome (9). With 
regard to the biologic functions of visfatin, a glucose 
reducing effect has been documented that activates 
the insulin signal via the insulin receptor, but in an 
alternative way to insulin (10). Visfatin is secreted by 
macrophages rather than adipocytes in adipose tis-
sue. Previously, visfatin was known as pre-B cell col-
ony enhancing factor (PBEF) because it plays a role 
in the development of early stage B cells. It exhibits 
an anti-apoptotic effect by inhibiting recombinant 
PBEF, caspase-3, and caspase-8. PBEF is an inflam-
matory cytokine that plays a basic role in delayed 
neutrophil apoptosis during sepsis. It can also be a 
useful biomarker in acute pulmonary injury. Visfatin 
induces matrix metalloproteinase activity in mono-
cytes, and TNF-α and IL-8 activity in peripheral blood 
mononuclear cells. In light of these findings, visfatin 
is involved in many pathological processes and can 
be considered an inflammatory mediator (3).
We compared the levels of the adipose tissue 
cytokines involved in inflammatory processes and 
associated with psoriasis in patients and healthy in-
dividuals, with the goal of exploring the relationship 
between these adipokines and psoriasis and disease 
severity. 
PATIeNTS AND MeTHODS
We enrolled 42 patients who had attended our 
Dermatology outpatient clinic and had been diag-
nosed histopathologically with psoriasis and another 
42 healthy subjects as the control group. The exclu-
sion criteria for both groups were less than 18 years 
of age, a diagnosis of erythrodermic or pustular pso-
riasis with only palmoplantar involvement, and re-
ceiving any kind of systemic treatment for psoriasis 
including acitretin, cyclosporine, methotrexate, bio-
logical agents, and all kinds of phototherapies in the 
last three months. Subjects with hypertension, ath-
erosclerotic cardiac disease, diabetes mellitus type 1 
or 2, chronic renal or liver disease, chronic obstructive 
pulmonary disease, neurological disorders, nutrition-
al disorders, autoimmune diseases, thyroid gland dis-
eases, immunosuppressive diseases, receiving treat-
ment, or having any infection at the time of diagnosis 
were also excluded from the study. The control group 
was selected from subjects with age, gender, and 
body mass index (BMI) similar to the patient group. 
BMI was calculated based on weight (kg) and height 
(cm). Type of psoriasis, duration of disease, previous 
and actual treatments, additional systemic diseases, 
and medications were all noted for each participant. 
The psoriasis area severity index (PASI) scoring was 
used to grade the severity of the disease.
Peripheral blood samples were obtained from the 
two groups after fasting for at least 8 hours. Blood 
samples were centrifuged at 4000 rpm and the serum 
was stored at -70ºC until the end of the study. Raybio 
Human Visfatin Enzyme Immunoassay kits (RayBio-
tech, Inc., Georgia, USA) were used to measure the 
serum levels of visfatin. Orgenium Human TNF-Alfa 
enzyme-linked immunosorbent assay (ELISA) and Or-
genium Human Adiponectin ELISA (Orgenium Labo-
ratories, Vantaa, Finland) kits were used to measure 
serum TNF-α and adiponectin, respectively. All sam-
ples were studied using the Bio-Rad Benchmark Plus 
(Bio-Rad Laboratories Inc., California, USA) device us-
ing ELISA. Written informed consent was obtained 
from all participants.
Statistical Analysis
An independent sample test was used for data 
with normal distribution to investigate differences 
between the two groups. For abnormally distributed 
data, the Mann-Whitney U test was used to establish 
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differences between the two groups. Correlation be-
tween the data was evaluated by the Pearson correla-
tion test. In all of the statistical tests, a P value less than 
0.05 was considered to be statistically significant.
ReSULTS
The psoriatic group included 23 male (54.8%) and 
19 female (45.2%) patients, and the control group 
included 19 male (45.2%) and 23 female (54.8%) 
subjects. The average age in the patient group was 
35.74±12.42 and 33.90±11.19 years in the control 
group. No significant differences were observed be-
tween the groups in terms of age or gender (P>0.05). 
BMI values were 25.81±4.92 in the patient group and 
24.12±3.91 in the control group; this difference was 
not statistically significant (P=0.084).
In the psoriatic group, 21 patients had plaque, 10 
patients had guttate, nine patients had plaque with 
guttate, one patient had the inverse, and one patient 
had palmoplantar with plaque type psoriasis. 
The mean PASI score was 6.12±4.31, and the mean 
duration of disease was 106.29±113.11 months in the 
patient group. 
The mean visfatin levels in the patient and control 
group were 6.94±2.29 ng/mL and 6.01±2.35 ng/mL, 
respectively. Although visfatin levels were higher 
in the patient group than in the control group, this 
difference was not statistically significant (P=0.73) 
(Table 1). No statistically significant correlation was 
observed between PASI and visfatin levels (P>0.05) 
(Table 2).
The mean serum adiponectin levels in the patient 
and control group were 6573.31±3393.72 ng/mL 
and 8320.21±3547.91 ng/mL, respectively. Adipo-
nectin levels in the patient group were significantly 
lower than in the control group (P=0.024) (Table 1). 
Comparison of PASI score and adiponectin levels re-
vealed a statistically significant linear correlation be-
tween these two parameters (P=0.004) (Table 2). The 
patient group had significantly higher TNF-α levels 
than the control group (101.97±31.95 pg/mL versus 
12.75±7.71 pg/mL, P=0.00) (Table 1).
A statistically significant linear correlation was 
found between PASI scores and the TNF-α levels 
(P=0.009) (Table 2). The clinical type of psoriasis 
was not significantly correlated with PASI score or 
TNF-α, adiponectin, or visfatin levels (Kruskal Wallis 
test, P>0.05). Within the psoriatic group, a small but 
statistically significant correlation was observed be-
tween the levels of TNF-α and adiponectin (r=0.311, 
p=0.045), while no significant correlation was ob-
served between the levels of adiponectin and visfa-
tin (p=0.536). Additionally, no statistically significant 
correlation was observed between the levels of TNF-α 
and visfatin (p=0.376) (Table 3). 
Within the patient group, no significant correla-
tion was observed between BMI and adiponectin or 
TNF-α levels, while a statistically significant positive 
correlation was observed between BMI and visfatin 
levels in this group (r=0.333, p=0.031). 
DISCUSSION
Psoriasis is one common immune-dependent in-
flammatory disease developing from immune-me-
diated mechanisms characterized by disruptions in 
key cytokines. Psoriasis is considered a multisystem 
disease, and is accompanied by many comorbidities. 
Table 1. Psoriasis area severity index (PASI), body mass index, tumor necrosis factor alpha (TNF-α), visfatin, 
and adiponectin levels in the patient and control group
n Mean±Standard deviation P 
PASI case 42 6.12±4.31 _
control
body mass index case 42 25.81±4.92
0.084control 42 24.12±3.90
TNF-α (pg/mL) case 42 101.97±31.95
0.00control 42 12.75±7.71
Visfatin (ng/mL) case 42 6,.4±2.29
0.73control 42 6.01±2.35
Adiponectin (ng/mL) case 42 6573.31±3393.72
0.024control 42 8320.21±3547.91
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Chronic inflammation is considered to play a role in 
the development of metabolic and vascular disorders 
(11,12). Metabolic syndrome, dyslipidemia, obesity, 
diabetes and insulin resistance, nonalcoholic fatty 
liver disease, and Crohn’s disease are potential co-
morbidities associated with psoriasis (13).
TNF-α increases the expression of many media-
tors such as IL-1, IL-6, IL-8, TGF-α, and GM-CSF. It also 
increases LTB4, PGE2, and adhesion molecules such 
as E-selectin, ICAM-1, and VCAM-1. Due to its mul-
tiple effects, TNF-α has a key role in the etiology of 
psoriasis. Studies have demonstrated reduction of 
this cytokine in serum and skin lesions after effective 
treatment, highlighting its importance in the patho-
genesis of psoriasis (14,15). Mussi et al. found that 
TNF-α levels were significantly higher compared to 
the control group, and found a significant relation-
ship between PASI scores and TNF-α levels. They also 
found that after effective treatment, both PASI scores 
and cytokine levels were significantly decreased (16). 
Ragab et al. reported that TNF-α levels were higher 
in patients with psoriasis, and that this elevation was 
more significant in severe compared to mild psoriasis 
(17). Arican et al. found that serum TNF-α, IFN-γ, IL-6, 
IL-8, IL-12, and IL-18 levels were significantly higher in 
patients with psoriasis than in the control group, but 
found no statistically significant relationship between 
TNF-α levels and disease severity (18). Borska et al. did 
not detect a significant difference in TNF-α levels be-
tween psoriatic patients and the control group (19). 
In our study, TNF-α values were significantly higher 
in the patient group than in the control group. Ad-
ditionally, we observed a statistically significant linear 
relationship between PASI and TNF-α levels in the pa-
tient group. These results suggest that TNF-α plays a 
role in the pathogenesis of psoriasis and may be used 
as a marker to assess disease severity.
Adiponectin is an anti-inflammatory adipokine 
and reduces the secretion of TNF-α and its inflamma-
tory response. However, adiponectin secretion is sup-
pressed by TNF-α and IL-6. Adiponectin and TNF-α an-
tagonize each other’s action in their target tissues. In 
vitro and in vivo experimental studies have revealed 
that adiponectin alleviates the unfavorable conse-
quences of proinflammatory cytokines, inhibits the 
release of adhesion molecules and the activation of 
the inflammatory signaling cascade, and prevents ox-
idative damage (3,4,20). Takahashi et al. reported that 
plasma adiponectin levels were statistically decreased 
in psoriasis patients and also reported a negative cor-
relation between plasma adiponectin levels and PASI 
scores (21). Kaur et al. found that plasma adiponectin 
levels were increased in normal-weight patients with 
psoriasis compared to levels in healthy controls or 
obese patients with psoriasis. They found no relation-
ship between adiponectin levels and PASI scores (22). 
Shibata et al. found that adiponectin levels were sig-
nificantly lower in patients than in the control group. 
However, they did not find a significant relationship 
between PASI scores and adiponectin levels (23). Co-
imbra et al. found that adiponectin levels were lower 
in patients with psoriasis, and also observed lower 
values in cases of moderate and severe psoriasis 
compared with mild cases (24). Oon et al. reported a 
positive correlation between adiponectin levels and 
PASI scores (25). In our study, as with previous studies, 
Table 2. Correlations between psoriasis area severity index (PASI) score and tumor necrosis factor alpha (TNF-











PASI   0.400 (0.009*) -0.021 (0.895) 0.438 (0.004*) 0.125 (0.428) 0.046 (0.772)
PASI: psoriasis area and severity index; BMI: body mass index; *P<0.05 was considered statistically significant
‘*’ can be added before p<0.05
Table 3. Correlations between tumor necrosis factor alpha (TNF-α), adiponectin, and visfatin levels with each 







TNF-α 0.311 (0.045*) 0.140 (0.376)
Adiponectin 0.311 (0.045*) -0.098 (0.536)
Visfatin 0.140 (0.376) -0.098 (0.536)
*p<0.05 was considered statistically significant
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adiponectin levels were statistically lower in patients 
with psoriasis compared with the control group. Our 
results indicate that the anti-inflammatory effects of 
adiponectin decreases in patients with psoriasis, po-
tentially speeding up the inflammatory process. We 
also observed a statistically significant linear relation-
ship between adiponectin levels and PASI scores. 
Studies investigating the relationship between adi-
ponectin and PASI scores in different centers have 
yielded contradictory results: no correlation, nega-
tive correlations, and positive correlations (21,22,25). 
Therefore, multifactorial reasons may affect the sever-
ity of psoriasis, and adiponectin levels may be a con-
tributing factor. We observed a statistically significant 
positive correlation between TNF-α and adiponectin 
levels in patients. Our results demonstrate that more 
case-controlled studies are needed to compare the 
relationship between adiponectin and TNF-α levels 
to arrive at a meaningful conclusion.
Visfatin can induce cellular expression of inflam-
matory cytokines such as TNF-α, IL-1, and IL-6. It also 
increases cell surface expression of co-stimulatory 
molecules such as CD54, CD40, and CD80. Visfatin 
expression is up-regulated in a variety of acute and 
chronic inflammatory diseases, including sepsis and 
rheumatoid arthritis, and plays a key role in the per-
sistence of inflammation through its capacity to in-
hibit neutrophil apoptosis (26). Koczan et al. focused 
on the gene expression profiles of peripheral blood 
mononuclear cells from patients with psoriasis suf-
fering from severe generalized disease, comparing 
the diseased stage and the cured stage. They tested 
expression of mRNA in peripheral blood mononu-
clear cells from 11 patients with psoriasis before and 
after treatment with dithranol. They found that IL-8, 
annexin A3, cyclooxygenase-2, cell cycle regulator 
G0S2, and visfatin expression were all increased dur-
ing illness. However, they included no data about the 
relationship between visfatin and other cytokines, 
the severity of the psoriasis, BMI, or the duration of 
disease (27). Zhou et al. found that psoriatic skin had 
increased tissue expression of visfatin (28). Bozkurt et 
al. found no statistically significant difference in the 
serum visfatin levels between patients with psoriasis 
and the control group, but found a slightly positive 
correlation between visfatin and PASI in patients (29). 
Ismail et al. found that serum visfatin levels were sig-
nificantly higher in patients with psoriasis compared 
with the control group and found a statistically signif-
icant positive correlation between PASI and visfatin 
levels (30). Gerdes et al. also reported that visfatin lev-
els were significantly higher in patients with psoriasis 
than in the control group (31). In our study, although 
visfatin levels were higher in patients with psoriasis 
than in the control group, the difference was not sta-
tistically significant. However, we observed a statisti-
cally significant correlation between PASI and visfatin 
levels, as well as a statistically significant positive cor-
relation between BMI and visfatin levels in patients. 
The relationship between BMI and visfatin is not yet 
clear. Some authors have reported increased visfatin 
levels in obese subjects and others have reported 
a negative correlation between visfatin and BMI 
(26,32). Our results suggest that visfatin is associated 
with visceral fat mass. In our study, patients did not 
have any systemic disease and the two groups did 
not differ significantly in terms of age, gender, and 
BMI, increasing the reliability of our results. Although 
no significant differences were observed in terms 
of gender or BMI between patients and the control 
group, the psoriasis group contained more men than 
the control group, and the average BMI was higher in 
the psoriasis group. These small differences may have 
affected our results. However, the disease severity of 
our patients with psoriasis was moderate and PASI 
scores were relatively low, so visfatin levels may be 
lower than expected due to this situation. 
CONCLUSION
Our results suggest that by triggering effects of 
inflammation of the adipose tissue cytokine, TNF-α 
plays a role in the inflammatory processes and the 
anti-inflammatory effects of adiponectin. However, 
the role of another adipokine, visfatin, is still unclear 
in psoriasis. Further studies including more patients 
with psoriasis with higher PASI scores are needed to 
investigate the role of visfatin in psoriasis pathogene-
sis. In addition, the relationship between adiponectin 
and TNF-α and the relationship between adiponectin 
and psoriasis severity need to be clarified. However, 
because of the cross-sectional character of the study 
it is difficult to determine if psoriasis is a cause or con-
sequence of the differences found in adipokine lev-
els.
The effects of TNF-α, which has been shown to 
affect the pathogenesis of psoriasis, has led the pos-
sibility of anti-TNF therapy, so a new epoch has been 
started together with biological agents in the treat-
ment of psoriasis, particularly in resistant cases. This 
situation has attracted attention to adipokines and 
has increased interest in new adipokines. 
Acknowledgements:
This study was supported by the Research Fund 
of the University of Abant Izzet Baysal. (Project no: 
2009.08.03.311)
Sereflican et al. Acta Dermatovenerol Croat
Visfatin, adiponectin and TNF-alpha in patients with psoriasis  2016;24(1):13-19
18 ACTA DERMATOVENEROLOGICA CROATICA
References:
1. Nestle FO. Psoriasis. Curr Dir Autoimmun 2008;10: 
65-75.
2.  Krueger G, Ellis CN. Ellis, Psoriasis--recent advan-
ces in understanding its pathogenesis and treat-
ment. J Am Acad Dermatol 2005;53:94-100.
3.  Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adi-
pokines: the missing link between insulin resis-
tance and obesity. Diabetes Metab 2008;34:2-11.
4.  Fonseca-Alaniz MH, Takada J, Alonso-Vale MIC, 
Lima FB. Adipose tissue as an endocrine organ: 
from theory to practice. Pediatr (Rio J) 2007;83:192-
203.
5.  Ahima RS, Flier JS. Adipose tissue as an endocrine 
organ. Trends Endocrinol Metab 2000;11:327-32.
6.  Chudek J, Wiecek A. Adipose tissue, inflamma-
tion and endothelial dysfunction. Pharmacol Rep 
2006;58 Suppl:81-8.
7.  Vazquez-Vela ME, Torres N, Tovar AR. White adip-
ose tissue as endocrine organ and its role in obe-
sity. Arch Med Res 2008;39:715-28.
8.  Guzik TJ, Mangalat D, Korbut R. Adipocytokines 
- novel link between inflammation and vascular 
function? J Physiol Pharmacol 2006;57:505-28.
9.  Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipoki-
nes and insulin resistance. Mol Med 2008;14:741-
51.
10.  Fukuhara A, Matsuda M, Nishizawa M, Segawa K, 
Tanaka M, Kishimoto K, et al. Visfatin: a protein 
secreted by visceral fat that mimics the effects of 
insulin. Science 2005;307:426-30.
11. Christophers E. Comorbidities in psoriasis. Clin 
Dermatol 2007;25:529-34.
12. Kalkan G, Karadağ S. The association between 
psoriasis and cardiovascular diseases. Eur J Gen 
Med 2013;10:10-16.
13. Gisondi P, Ferrazi A, Girolomoni G. Metabolic co-
morbidities and psoriasis. Acta Dermatovenereol 
Croat 2010;18:297-304.
14. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J 
Dermatol 1999;38:241-251.
15. Victor FC, Gottlieb AB, Menter A. Changing para-
digms in dermatology: tumor necrosis factor al-
pha (TNF-alpha) blockade in psoriasis and psoria-
tic arthritis. Clin Dermatol 2003;21:392-97.
16. Mussi A, Bonifati C, Carducci M, D’Agosto G, Pim-
pinelli F, D’Urso D, et al. Serum TNF-alpha levels 
correlate with disease severity and are reduced 
by effective therapy in plaque-type psoriasis. J 
Biol Regul Homeost Agents 1997;11:115-18.
17. Ragab HM, El Maksoud NA, Farid Roaiah MM. Bio-
chemical significance of proinflammatory cytoki-
nes in psoriasis vulgaris among Egyptian patients. 
J Am Sci 2010;6:423-9.
18. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels 
of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, 
and IL-18 in patients with active psoriasis and cor-
relation with disease severity. Mediators Inflamm 
2005;2005:273-79.
19. Borská L, Fiala Z, Krejsek J, Andrýs C, Vokurková D, 
Hamáková K, et al. Selected immunological chan-
ges in patients with Goeckerman’s therapy TNF-
alpha, sE-selectin, sP-selectin, sICAM-1 and IL- 8. 
Physiol Res 2006;55:699-706.
20. Shetty S, Kusminski CM, Scherer PE. Adiponectin 
in health and disease: evaluation of adiponectin-
targeted drug development strategies. Trends 
Pharmacol Sci 2009;30:234-9.
21. Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Is-
hida-Yamamoto A, et al. Plasma adiponektin and 
leptin levels in Japanese patients with psoriasis. 
Br J Dermatol 2008;159:1207-8.
22. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. 
Clear differences in adiponectin level and gluta-
thione redox status revealed in obese and nor-
mal-weight patients with psoriasis. Br J Dermatol 
2008;159:1364-67.
23. Shibata S, Saeki H, Tada Y, Karakawa M, Komine 
M, Tamaki K. Serum high molecular weight adip-
onectin levels are decreased in psoriasis patients. 
J Dermatol Sci 2009;55:62-3.
24. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quin-
tanilha A, et al. Circulating levels of adiponectin, 
oxidized LDL and C-reactive protein in Portu-
guese patients with psoriasis vulgaris, according 
to body mass index, severity and duration of the 
disease. J Dermatol Sci 2009;55:202-4.
25. Oon HH, Liew CF, Theng CCT, Ho MSL. Adiponec-
tin is associated with disease activity of psoriasis 
(abstract). J Am Acad Dermatol 2009;60:AB 163. 
Abstract P 3307.
26. Luk T, Malam Z, Marshall JC. Pre-B cell colony-en-
hancing factor (PBEF)/visfatin: a novel mediator of 
innate immunity. J Leukoc Biol 2008;83:804-16.
27. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt 
G, Krentz H, et al. Gene expression profiling of pe-
ripheral blood mononuclear leukocytes from pso-
Sereflican et al. Acta Dermatovenerol Croat
Visfatin, adiponectin and TNF-alpha in patients with psoriasis  2016;24(1):13-19
19ACTA DERMATOVENEROLOGICA CROATICA
riasis patients identifies new immune regulatory 
molecules. Eur J Dermatol 2005;15:251-57.
28. Zhou X, Krueger JG, Kao MCJ, Lee E, Du F, Menter 
A, et al. Novel mechanisms of T-cell and dendritic 
cell activation revealed by profiling of psoriasis on 
the 63,100-element oligonucleotide array. Physiol 
Genomics 2003;13:69-78.
29. Bozkurt NM, Yıldırım M, Ceyhan AM, Kara Y, Vural 
H. Psoriasisli hastalarda serum visfatin düzeyleri-
nin araştırılması. Turkderm 2010;44:15-8.
30. Ismail SA, Mohamed SA. Serum levels of visfa-
tin and omentin-1 in patients with psoriasis and 
their relation to disease severity. Br J Dermatol 
2012;167:436-9.
31. Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, 
Weichenthal M, Mrowietz U. Leptin, adiponectin, 
visfatin and retinol-binding protein-4 mediators 
of comorbidities in patients with psoriasis? Exp 
Dermatol 2012;21:43-7.
32. Chen CC, Li TC, Li CI, Liu CS, Lin WY, Wu MT, et al. 
The relationship between visfatin levels and an-
thropometric and metabolic parameters: associa-
tion with cholesterol levels in women. Metabolism 
2007;56:1216-20.
Sereflican et al. Acta Dermatovenerol Croat
Visfatin, adiponectin and TNF-alpha in patients with psoriasis  2016;24(1):13-19
